The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 1, 2004, Pages

  Palmer, Andrew J ^a   Roze, Stéphane ^a   Valentine, William J ^a   Minshall, Michael E ^b   Foos, Volker ^a   Lurati, Francesco M ^a   Lammert, Morten ^a   Spinas, Giatgen A ^a  

^a IQVIA   (United States)

^b CORE USA LLC ^*  (United States)

Author keywords

Complications; Cost effectiveness; Costs; Diabetes; Health economics; Modelling

Indexed keywords

AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; EYE DISEASE; FOOT ULCER; HEALTH CARE COST; HEALTH CARE POLICY; HYPOGLYCEMIA; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; INTERNET; LACTIC ACIDOSIS; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MONTE CARLO METHOD; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; STROKE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DATABASES; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INTERNET; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 5344261712     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X1980     Document Type: Article

References (118)

1. Pharmaceutical Benefits Advisory Committee. Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC. 2002.
2. A proposal for methodological guidelines for economic evaluations of pharmaceuticals. Gent: Belgian Society for Pharmacoepidemiology BESPE, 1995.
3. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluations of pharmaceuticals: Canada. 1997. Ottawa, CCOHTA.
4. Hannover Consensus Group. German recommendations for healthcare economic evaluation studies. Revised version of the Hannover consensus. Med Klin 2000; 95(1):52-5.
5. Capri S, Ceci A, Terranova L. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information Journal 2001; 35(1):189-201.
6. National Institute for Clinical Excellence. Guide to the technology appraisal process. 2001.
7. Sullivan SD, Lyles A, Luce B et al. AMCP guidelines for submission of clinical and economic evaluation data to support formulary listing in the US health plans and pharmacy benefits management organizations. J Managed Care Pharm 2001; 7:272-82.
8. The Regence Group. The Reference Group Formulary Submission Guidelines 2002. A format for submission of clinical and economic evaluation data in support of reimburement and formulary consideration to the Regence Group. The Regence Group 2002.
9. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6(1):9-17.
10. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78:809A-F.
11. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26(8):2300-4.
12. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21(4):518-24.
13. Takiya L, Chawla S. Therapeutic options for the management of type 2 diabetes mellitus. Am J Manag Care 2002; 8(11):1009-23.
14. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl 5:S1-85.
15. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782-7.
16. Uusitupa M, Siitonen O, Aro A, Pyorala K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1985; 28(1):22-7.
17. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16(4):642-52.
18. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(2):89-94.
19. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331(21):1428-36.
20. Kretowski A, Kowalska I, Peczynska J, Urban M, Green A, Kinalska I. The large increase in incidence of Type I diabetes mellitus in Poland. Diabetologia 2001; 44 Suppl 3:B48-B50.
21. Podar T, Solntsev A, Karvonen M, Padaiga Z, Brigis G, Urbonaite B et al. Increasing incidence of childhood-onset type I diabetes in 3 Baltic countries and Finland 1983-1998. Diabetologia 2001; 44 Suppl 3:B17-20.
22. Pundziute-Lycka A, Dahlquist G, Nystrom L, Amqvist H, Bjork E, Blohme G et al. The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0-34 years group in Sweden 1983-1998. Diabetologia 2002; 45(6):783-91.
23. Weets I, De Leeuw IH, Du Caju MV, Rooman R, Keymeulen B, Mathieu C et al. The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 2002; 25(5):840-6.
24. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341(8850):927-8.
25. Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993; 9(4):289-93.
26. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type 1 diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998; 41(5):536-41.
27. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20(5):725-34.
28. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50 Suppl 3:S15-46.
29. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50 Suppl 3:S47-S56.
30. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26(11):3093-101.
31. National Diabetes Data Group, ed. Diabetes in America. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995; Chapters 8, 9, 12-20:165-220, 259-456.
32. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9):1414-31.
33. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1 edn. New York: Oxford University Press, 1996.
34. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13(4):322-8.
35. Lang DL, Lopert R, Hill SR. Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials. J Clin Pharm Ther 2003; 28(5):433-9.
36. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986; 6(2):85-92.
37. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5(2):157-77.
38. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18(3):337-46.
39. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19(6):609-21.
40. Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20(12):855-67.
41. Scottish Medicines Consortium. Guidance to manufacturers, notes for the completion of the new product assessment form (version 2). Scottish Medicines Consortium. 1-1-0004. 1-29-2004.
42. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160(8):1093-100.
43. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139(2 Pt 1):272-81.
44. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101(6):671-9.
45. Herlitz J, Bang A, Karlson BW. Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 1996; 87(5):423-8.
46. Sonke GS, Beaglehole R, Stewart AW, Jackson R, Stewart FM. Sex differences in case fatality before and after admission to hospital after acute cardiac events: analysis of community based coronary heart disease register. BMJ 1996; 313(7061):853-5.
47. Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ryden L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 2000; 21(9):733-9.
48. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314(7093):1512-15.
49. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134(8):629-36.
50. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159(11):1197-204.
51. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88(1):107-15.
52. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347(18):1397-402.
53. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258):405-12.
54. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200):253-9.
55. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991; 22:312-18.
56. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002; 33(7):1776-81.
57. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50(1):208-16.
58. Sprafka JM, Virnig BA, Shahar E, McGovern PG. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabet Med 1994; 11(7):678-84.
59. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2002; 25(90001):S78-S79.
60. Buring JE, Hennekens CH. Prevention of cardiovascular disease: risks and benefits of aspirin. J Gen Intern Med 1990; 5(5 Suppl):S54-S57.
61. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96(1):44-9.
62. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2):156-63.
63. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intem Med 1995; 122:561-8.
64. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321(7258):412-19.
65. Tull ES, Roseman JM. Diabetes in African Americans. In: National Diabetes Data Group, editor. Diabetes in America. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995:613-30.
66. Ghodes D. Diabetes in North American Indians and Alaska Natives. In: National Diabetes Data Group, ed. Diabetes in America. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 21995:683-702.
67. Stern MP, Mitchell BD. Diabetes in Hispanic Americans. In: National Diabetes Data Group, ed. Diabetes in America. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995:631-60.
68. Tennvall GR, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 2001; 44:2077-87.
69. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995; 113(1):36-51.
70. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications. The perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45:1289-98.
71. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
72. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352(9145):1978-81.
73. Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17(8):909-17.
74. Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiology study of Diabetic Retinopathy. IX. Four year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107:237-43.
75. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus [see comments]. Lancet 1998; 351(9095):28-31.
76. Janghorbani MB, Jones RB, Allison SP. Incidence of and risk factors for cataract among diabetes clinic attenders. Ophthalmic Epidemiol 2000; 7(1):13-25.
77. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
78. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47:1703-20.
79. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27(2):167-94.
80. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341(23):1725-30.
81. U.S. Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2001.
82. UK Renal Registry Report 2002. Bristol: UK Renal Registry, 2002.
83. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35(4):695-707.
84. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158(9):998-1004.
85. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118(8):577-81.
86. Lewis EJ, Hunsicke LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
87. UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
88. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-13.
89. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46(2):271-86.
90. Stepka M, Rogala H, Czyzyk A. Hypoglycemia: a major problem in the management of diabetes in the elderly. Aging (Milano) 1993; 5(2):117-21.
91. Ben Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999; 159(3):281-4.
92. Morris AD, Boyle DI, McMahon AD, Pearce H, Evans JM, Newton RW et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997; 20(9):1363-7.
93. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345(8959):1195-8.
94. Maclsaac RJ, Lee LY, McNeil KJ, Tsalamandris C, Jerums G. Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J 2002; 32(8):379-85.
95. Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci 1996; 311(5):225-33.
96. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl 1985; 15:105-11.
97. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin [letter]. N Engl J Med 1998; 338(4):265-6.
98. National Vital Statisitics Reports, Sept 21, 2001.
99. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21):2005-12.
100. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22(4):340-9.
101. Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia. 2003.
102. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38(6):583-637.
103. Fairman KA, Motheral BR. Do decision-analytic models identify cost-effective treatments? A retrospective look at Helicobacter pylori eradication. J Manag Care Pharm 2003; 9(5):430-40.
104. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20(Suppl 1):S27-S40.
105. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46 Suppl 1:M17-M21.
106. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23(16):1267.
107. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346):1623-30.
108. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34(1):83-9.
109. Qiao Q, Pyorala K, Nissinen A, Lindstrom J, Tilvis R, Toumilehto J. 2-hour glucose is a continuous and independent risk predictor for incident coronary heart disease and stroke and cardiovascular mortality. Eur Heart J 2002; 23(16):1267-75.
110. Grzybowski M, Younger JG. Statistical methodology: III. Receiver operating characteristic (ROC) curves. Acad Emerg Med 1997; 4(8):818-26.
111. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25(3):1017-38.
112. DRG Guidebook. A comprehensive resource to the DRG classification system. 17 edn. St. Anthony Publishing, 2001.
113. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003; 26(8):2305-10.
114. 2000 Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 2000.
115. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intem Med 1999; 131(9):660-7.
116. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001; 27(4):347-51.
117. Carrington AL, Mawdsley SK, Morley M, Kincey J, Boulton AJ. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996; 32(1-2):19-25.
118. NICE. National Institute for Clinical Excellence. Technology appraisal guidance - No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. 1-12-2002.